These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 33875509)

  • 1. Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course.
    Pagali S; Edquist C; O'Rourke N
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33875509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
    Mock CM; Schwetschenau KH
    Am J Health Syst Pharm; 2012 Jan; 69(1):35-9. PubMed ID: 22180549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-hyperammonaemia valproate-induced encephalopathy: A case report.
    Chen L; Xu Z; Huang H
    J Clin Pharm Ther; 2022 Mar; 47(3):415-419. PubMed ID: 34462930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid induced hyperammonaemic encephalopathy.
    Amanat S; Shahbaz N; Hassan Y
    J Pak Med Assoc; 2013 Jan; 63(1):72-5. PubMed ID: 23865136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients.
    Nicholson C; Fowler M; Mullen C; Cunningham B
    Epilepsy Res; 2021 Dec; 178():106806. PubMed ID: 34763268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate-induced fatal acute hyperammonaemia-related encephalopathy in late-onset ornithine transcarbamylase deficiency.
    Kazmierski D; Sharma N; O'Leary K; Ochieng P
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34035022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.
    Ranjith S; Abeysundera H; Jeyaranjan H
    BMJ Case Rep; 2023 Nov; 16(11):. PubMed ID: 38035682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levocarnitine for the Treatment of Valproic Acid-Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center.
    Glatstein M; Bonifacio Rino P; de Pinho S; Scolnik D; Pivko-Levi D; Hoyte C
    Am J Ther; 2019; 26(3):e344-e349. PubMed ID: 29232283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate overdose leading to hyperammonaemic encephalopathy.
    Sharma DS; Gupta S; Sharma P
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37423637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy.
    Izadi Firouzabadi L; Geer K; Mead P;
    Postgrad Med J; 2018 Nov; 94(1117):664. PubMed ID: 30397004
    [No Abstract]   [Full Text] [Related]  

  • 11. Valproic Acid Overdose: Case Report and Literature Review.
    Patel J; Berezowski I; Mazer-Amirshahi M; Frasure SE; Tran QK; Pourmand A
    J Emerg Med; 2022 Nov; 63(5):651-655. PubMed ID: 36229318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperammonemic encephalopathy induced by valproic acid.
    Zhu QM; Singh AK; Chang HR; Konka SA
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38350699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A severe, reversible encephalopathy after prolonged use of valproic acid].
    van Haaren PCF; Bloemkolk D; Rundervoort RS; Gerritse FL
    Tijdschr Psychiatr; 2023; 65(1):50-53. PubMed ID: 36734691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of valproic acid poisoning treated with L-carnitine.
    Chan YC; Tse ML; Lau FL
    Hum Exp Toxicol; 2007 Dec; 26(12):967-9. PubMed ID: 18375641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy.
    Khakwani A; Gannon D
    J R Coll Physicians Edinb; 2019 Dec; 49(4):301-303. PubMed ID: 31808457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review.
    Brown LM; Cupples N; Moore TA
    Ment Health Clin; 2018 May; 8(3):148-154. PubMed ID: 29955560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
    Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M
    Medicine (Baltimore); 2017 Sep; 96(39):e8117. PubMed ID: 28953637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carnitine in the treatment of valproic acid-induced toxicity.
    Lheureux PE; Hantson P
    Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
    Al-sharefi A; Bilous R
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26336183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case report of valproate encephalopathy].
    Miyamoto T; Miyamoto M; Hirata K; Katayama S
    Rinsho Shinkeigaku; 1999 Oct; 39(10):1075-7. PubMed ID: 10655774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.